- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ind-Swift Labs gets USFDA EIR for Derabassi API facility
Mumbai: Ind-Swift Laboratories Limited has received the Establishment Inspection Report (EIR) from the USFDA, for the Surveillance GMP inspection of its API manufacturing facility located at Derabassi, Punjab."The USFDA inspection was conducted from 09th March 2020 to 13th March 2020. The EIR has been issued without any FORM 483 observations", Company addedThis is the Sixth Successful...
Mumbai: Ind-Swift Laboratories Limited has received the Establishment Inspection Report (EIR) from the USFDA, for the Surveillance GMP inspection of its API manufacturing facility located at Derabassi, Punjab.
"The USFDA inspection was conducted from 09th March 2020 to 13th March 2020. The EIR has been issued without any FORM 483 observations", Company added
This is the Sixth Successful USFDA inspection completed by the Company. IndSwift Supplies 15 APIs to its customers based in the U.S.
The APIs manufactured from the Derabassi Manufacturing facility are supplied across the world to over 70 countries covering more than 280 customers including all the major drug manufacturers across the Globe.
Ind-Swift Laboratories Ltd is a global manufacturer of APIs, Intermediates, and formulations (through group collaboration) headquartered in Chandigarh, India.
With regulated 6+ manufacturing sites in Punjab and Jammu, it caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW.
Read also: Dr Reddy's Labs gets USFDA inspection closure report for Srikakulam plant
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751